on NanoViricides, Inc. (NASDAQ:NNVC)
NanoViricides to Showcase at Boston's BIO International Convention
NanoViricides, Inc., a leader in broad-spectrum antiviral drugs, will present at the BIO International Convention in Boston on June 16, 2025. Dr. Anil R. Diwan, the company’s President, will discuss the firm’s drug pipeline and platform technologies available for licensing.
The highlight is NV-387, a promising candidate advancing towards Phase II trials for MPOX treatment amidst a global health emergency. Designed to cover a broad antiviral spectrum, NV-387 has shown effectiveness against major respiratory viruses.
Additionally, the company will discuss its pan-herpesvirus drug candidate, NV-HHV-1, and an anti-HIV candidate, NV-HIV-1, both demonstrating strong preclinical results.
NanoViricides also promotes its nanoviricide platform enabling drug rescue and targeted delivery technology, enhancing the potential efficacy of challenging drug candidates.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NanoViricides, Inc. news